Venlafaxine for treatment of interferon alfa-induced depression.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Parviz Malek-Ahmadi.
Explore the source record for details and available documents.
A 38-year-old woman with medication-resistant major depression and posttraumatic stress disorder was treated with electroconvulsive therapy (ECT) concurrent with a duloxetine-olanzapine combination. The treatment resulted in complete resolution of major depression without any complications. This case report suggests that treatment with the combination of duloxetine and olanzapine concurrently with ECT was found safe and uncomplicated. The literature on the combined use of antidepressants and ECT is briefly reviewed.
OBJECTIVE: To report the effect of oxcarbazepine in a patient with bipolar illness and posttraumatic stress disorder (PTSD). CASE SUMMARY: A 38-year-old white woman with PTSD and bipolar disorder who had partially responded to carbamazepine was treated with oxcarbazepine. Within a month of initiation of treatment with oxcarbazepine, she reported progressive improvement in her PTSD symptoms. As oxcarbazepine monotherapy with 750 mg twice daily continued, she reported significant reduction of her PTSD symptoms and stabilization of her mood. She tolerated oxcarbazepine without adverse effects. DISCUSSION: PTSD symptoms tend to wax and wane. Spontaneous remission also occurs in some patients with PTSD. There are a few reports indicating that carbamazepine alleviates PTSD symptoms. Since oxcarbazepine is an analog of carbamazepine, it is theorized that oxcarbazepine also has efficacy in significantly reducing PTSD symptoms. CONCLUSIONS: There are case reports and uncontrolled studies suggesting that antiepileptic drugs (AEDs) alleviate PTSD symptoms. Oxcarbazepine may also benefit patients with PTSD. However, controlled studies are needed to investigate the use of AEDs in patients with PTSD and bipolar disorder.
OBJECTIVE: To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy. CASE SUMMARY: A 43-year-old white woman with chronic hepatitis C and severe IFN-induced depression was treated with sustained-release bupropion initiated at 150 mg/day for 7 days and 100 mg twice daily thereafter. The dosage was increased again, to 350 mg/day when depressive symptoms recurred. While receiving that dose and continuing IFN treatment, she reported significant improvement in her depressive symptoms without experiencing any adverse effects. DISCUSSION: There is limited evidence suggesting that IFNs decrease central serotonergic transmission. There are several published reports on the use of selective serotonin-reuptake inhibitors for the treatment of IFN-induced depression. However, controlled studies are needed to assess the efficacy of serotonergic and noradrenergic antidepressants in IFN-treated patients with depressive symptoms. CONCLUSIONS: Sustained-release bupropion might be of potential benefit in patients with interferon-induced depression.
OBJECTIVE: To report the effects of gabapentin in a patient with concurrent depression and posttraumatic stress disorder (PTSD) and review the use of antiepileptic drugs (AEDs) in PTSD. CASE SUMMARY: A 37-year-old Latin American woman was being treated for major depression and PTSD. While the depressive symptoms were in remission, she reported a significant reduction in the frequency of her flashbacks after gabapentin was added to venlafaxine. She did not receive any type of psychotherapy. The flashbacks recurred after she discontinued gabapentin. DISCUSSION: While the improvement reported by the patient may have been related to a placebo effect or spontaneous recovery, treatment with gabapentin may have played a role in alleviating the flashbacks. Other published reports suggest that AEDs have a beneficial effect on some PTSD symptoms. CONCLUSIONS: AEDs may be of some therapeutic value in patients with PTSD. Future controlled studies are warranted to investigate the effectiveness of these agents.
The 1990 American Psychiatric Association (APA) Task Force report on electroconvulsive therapy (ECT) suggests that there is an increased risk of complications in patients with intracranial vascular masses. There have been only a few published reports on the use of ECT in these patients. In this case report, an additional case is described that used ECT in the treatment of major depression in a 72-year-old patient with a venous angioma involving the left cerebellum. Brain imaging studies, neurosurgery, cardiology, and orthopedic consultations were obtained prior to ECT. Blood pressure was monitored closely throughout the course of ECT. Prior to each ECT, antihypertensive medication was given in addition to other pretreatment medications. Consistent with previously published reports, the patient did not experience any neurological deterioration or adverse effects. A brief review of the literature on the use of ECT in patients with venous angioma and other intracranial vascular masses is presented.
A 27-year-old woman with severe psychosis and mania associated with systemic lupus erythematosus was successfully treated with electroconvulsive therapy. Cyclophosphamide was given as an adjuvant. The use of electroconvulsive therapy in patients with lupus and psychiatric disorders is discussed.
A 40-year-old depressed patient with alpha(1)-antitrypsin deficiency and severe emphysema developed bronchospasm shortly after an initial electroconvulsive therapy (ECT), resulting in discontinuation of treatment. The use of ECT in patients with emphysema and prevention of respiratory complications are discussed.
An elderly female patient with major depression was found to have an asymptomatic chronic subdural hematoma. Electroconvulsive therapy (ECT) resulted in full remission of her depression without neurological deterioration. The use of ECT in patients with cerebral lesions is discussed.
An elderly depressed female patient, who tolerated antidepressant drugs poorly, was found to have a small and asymptomatic meningioma before she was given electroconvulsive therapy (ECT). She received seven bilateral ECTs without neurological deterioration and had a good clinical result.
An elderly female patient with major depression and persistent tardive dyskinesia was treated with electroconvulsive therapy (ECT). In addition to complete recovery from depression, a significant improvement was also observed in her symptoms of tardive dyskinesia. Further study of the effects of ECT on tardive dyskinesia is warranted.